Trump's State of the Union address highlighted his year-one milestones, including tax reform, expanded defense budget, and stock market performance. Ben Phillips, Chief Investment Officer at EventShares, was with us to discuss how the speech could impact markets.
Stocks rebounded from a 2-day sell-off the day after President Trump delivered his speech. Phillips says his tone was more presidential, and the markets were responding positively. Phillips highlighted tax reform as a catalyst for more gains for the year ahead, saying it is a major boost to many corporations.
President Trump called on Congress for a bill that raises $1.5 billion on infrastructure. EventShares created the first-ever policy driven portfolios. Phillips gave insight into which stocks could benefit based off policies from the GOP and Democrats. Phillips also said he was concerned stocks could be hitting a top.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
